Mobile

An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanom...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005203-18

An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The safety and clinical activity of recMAGE-A3 + AS01B in patients with MAGE-A3-positive metastatic cutaneous melanoma.

Critère d'inclusion

  • MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma

Liens